Ruben A. Mesa, MD
Advertisement
Articles by Ruben A. Mesa, MD
Advertisement
Latest Updated Articles
Novel Therapy in Myelofibrosis: MomelotinibPublished: January 5th 2023 | Updated:
Therapy in Myelofibrosis: PacritinibPublished: January 5th 2023 | Updated:
Therapy in Myelofibrosis: Fedratinib and Ruxolitinib StrategiesPublished: January 12th 2023 | Updated:
Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNsPublished: August 13th 2020 | Updated:
Dr. Mesa on Remaining Challenges Faced in MPN TreatmentPublished: October 15th 2020 | Updated:
Myelofibrosis: Nuancing the Potential of Disease ModificationPublished: January 12th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5